The most effective natural Atherosclerosis treatment
Click on a box to see what we consider
the most effective natural Atherosclerosis treatment for you

WOMEN 39
AND UNDER		 MEN 39
AND UNDER		 WOMEN 40
AND UP		 MEN 40
AND UP
click here...click here...click here...click here...

What is Atherosclerosis?

Atherosclerosis or arteriosclerosis is a common disorder of the arteries characterised by plaque buildup and hardening of the arteries, leading to reduced blood flow and a higher risk of blood clots, organ damage and premature death.

The cause of atherosclerosis is still being debated, but many scientists agree that inflammation and elevated oxidative stress play a decisive role. Combining lifestyle changes, lowering of LDL (unhealthy) cholesterol (only if it is too high) and providing the body with natural anti-inflammatory and antioxidant nutrients reduce the incidence and progression of atherosclerosis.

Which natural ingredients can have an effect on atherosclerosis?

Tocotrienols, polymethoxylated flavonoids (tangeretin and nobiletin), grape seed extract, fish oils (EPA/DHA), green tea extract, hawthorn extract, magnesium, chromium, selenium, vitamins B3 and C, quercetin, ginger root extract, gingko biloba and many more.

What effects do these ingredients have?

  • Lower total cholesterol by up to 30%.
  • Lower LDL (unhealthy) cholesterol by up to 27%.
  • Enhance HDL (healthy) cholesterol.
  • Lower triglycerides by up to 34%.
  • Improve LDL/HDL ratio by up to 27%.
  • Reduce plaque build-up.
  • Reduce inflammation.
  • Lower elevated levels of homocysteine.
  • Inhibit pathological thrombocyte aggregation.
  • Dilate blood vessels.

For the reader with a deeper interest:

How do these ingredients work?

  • Treat and prevent vitamin and mineral deficiencies.
  • Anti-inflammatory and antioxidant effects.
  • Lower CRP (C-reactive protein) produced during inflammation.
  • Lower apolipoprotein B (ApoB).
  • Inhibit diacylglycerol acetyl transferase (DGAT) enzymes.
  • Enhance the breakdown rate of HMG-CoA reductase enzymes.
  • Inhibit micros malt triglycerides transfer protein.
  • Enhance hepatocellular PPARa.
  • Inhibit the synthesis of tumour necrosis factor a.
  • Inhibit the synthesis of interleukin-10, IL-1, IL-8 and GM-CSF.,
  • Inhibit the synthesis of macrophage inflammation protein-1a.
  • Inhibit the synthesis of other inflammatory cytokines.
  • Inhibit ischemic tissue damage.
  • Inhibit lipid peroxidation.

The information above is based on more than 42,000 articles published in scientific journals and which are available at MEDLINE, the world’s largest medical database. Below you will find a few of them listed:

References

  1. Ando M, Sanaka T, Nihei H. Eicosapentanoic acid reduces plasma levels of remnant lipoproteins and prevents in vivo peroxidation of LDL in dialysis patients. J Am Soc Nephrol 1999;10:2177–84.
  2. Antoniades C, Tousoulis D, et al. Vascular endothelium and inflammatory process, in patients with combined Type 2 diabetes mellitus and coronary atherosclerosis: The effects of vitamin C. Diabet Med. 2004 Jun;21(6):552–8.
  3. Balz F. Antioxidant Vitamins and Heart Disease. Presented at the 60th Annual Biology Colloquium, Oregon State University, February 25, 1999.
  4. Beckman JA, Creager MA, et al. Diabetes and atherosclerosis: Epidemiology, pathophysiology, and management. JAMA. 2002;287(19):2570–81.
  5. Belcher JD, Balla J, Balla G, et al. Vitamin E, LDL, and endothelium: Brief oral vitamin supplementation prevents oxidized LDL-mediated vascular injury in vitro. Arterioscler Thromb 1993;13:1779–89.
  6. Benagiano G, Farris M. Why a consensus conference on hormone replacement therapy and the cardiovascular system? Maturitas. 2004;47(4):245–53.
  7. Bertelli AA, Giovanninni L, Bernini W, et al. Antiplatelet activity of cis-resveratrol. Drugs Exp Clin Res 1996;22(2):61–3.
  8. Boberg M, Vessby B, Selinus I. Effects of dietary supplementation with n-6 and n-3 long-chain polyunsaturated fatty acids on serum lipoproteins and platelet function in hypertriglcyeridaemic patients. Acta Med Scand 1986;220:153–60.
  9. Bordia A, Verma SK, Srivastava KC. Effect of ginger (Zingiber officinale Rosc) and fenugreek (Trigonella foenumgraceum L) on blood lipids, blood sugar, and platelet aggregation in patients with coronary artery disease. Prostagland Leukotrienes Essential Fatty Acids 1997;56:379–84.
  10. Bots ML, Elwood PC, et al. Level of fibrinogen and risk of fatal and non-fatal stroke. EUROSTROKE: a collaborative study among research centres in Europe. J Epidemiol Community Health. 2002;56 Suppl 1:i14–18.
  11. Bueno R, Alvarez de Sotomayor M, et al. L-carnitine and propionyl-L-carnitine improve endothelial dysfunction in spontaneously hypertensive rats: Different participation of NO and COX-products. Life Sci. 2005 Sep 9;77(17):2082–97.
  12. Chambers JC, McGregor A, Jean-Marie J, et al. Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia. An effect reversible with vitamin C therapy. Circulation 1999;99:1156–60.
  13. Chen CK, Pace-Asciak. CR. Vasorelaxing activity of resveratrol and quercetin in isolated rat aorta. Gen Pharm 1996;27(2):363–6.
  14. Cockcraft JR. Exploring vascular benefits of endothelium-derived nitric oxide. Am J Hypertens. 2005 Dec;18(12 Pt 2):177S–83S. Review.
  15. Di Napoli M, Papa F, et al. Prognostic influence of increased C-reactive protein and fibrinogen levels in ischemic stroke. Stroke. 2001;32(1):133–8.
  16. Dietrich M, Block G, et al. Antioxidant supplementation decreases lipid peroxidation biomarker F(2)-isoprostanes in plasma of smokers. Cancer Epidemiol Biomarkers Prev. 2002;11(1):7–13.
  17. Fang JC, Kinlay S, et al. Effect of vitamins C and E on progression of transplant-associated arteriosclerosis: A randomised trial. Lancet. 2002;359(9312):1108–13.
  18. Folsom AR, Nieto FJ, McGovern PG, et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins. Circulation 1998;98:204–10.
  19. Frei B. Ascorbic acid protects lipids in human plasma and low-density lipoprotein against oxidative damage. Am J Clin Nutr 1991;54:1113S–8S.
  20. Guilland JC, Favier A, et al. [Hyperhomocysteinemia: An independent risk factor or a simple marker of vascular disease? 2. Epidemiological data]. Pathol Biol (Paris). 2003;51(2):111–21.
  21. Haglund O, Luostarinen R, Wallin R, et al. The effects of fish oil on triglycerides, cholesterol, fibrinogen and malondialdehyde in humans supplemented with vitamin E. J Nutr 1991;121:165–9.
  22. Haglund O, Luostarinen R, Wallin W, Saldeen T. Effects of fish oil on triglycerides, lipoprotein(a), atherogenic index and fibrinogen. Influence of the degree of purification of the oil. Nutr Res 1992;12:455–68.
  23. Haglund O, Wallin R, Luostarinen R, Saldeen T. Effects of a new fluid fish oil concentrate, ESKIMO-3, on triglycerides, cholesterol, fibrinogen and blood pressure. J Intern Med 1990;227:347–53.
  24. Hak AE, Witteman JC, et al. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: The Rotterdam study. J Clin Endocrinol Metab. 2002;87(8):3632–9.
  25. Harris A, Devaraj S, et al. Oxidative stress, alpha-tocopherol therapy, and atherosclerosis. Curr Atheroscler Rep. 2002;4(5):373–80.
  26. Haynes WG. Hyperhomocysteinemia, vascular function and atherosclerosis: Effects of vitamins. Cardiovasc Drugs Ther. 2002;16(5):391–9.
  27. Hertog MGL, Sweetnam PM, Fehily AM, et al. Antioxidant flavonols and ischemic heart disease in a Welsh population of men: the Caerphilly Study. Am J Clin Nutr 1997;65:1489–94.
  28. Hibatallah J, Carduner C, et al. In-vivo and in-vitro assessment of the free-radical-scavenger activity of Ginkgo flavone glycosides at high concentration. J Pharm Pharmacol. 1999;51(12):1435–40.
  29. Horrobin DF, Manku MS. How do polyunsaturated fatty acids lower plasma cholesterol levels? Lipids 1983;558–62.
  30. Janisch KM, Williamson G, et al. Properties of quercetin conjugates: Modulation of LDL oxidation and binding to human serum albumin. Free Radic Res. 2004;38(8):877–84.
  31. Janssen PL, Meyboom S, van Staveren WA, et al. Consumption of ginger (Zingiber officinale Roscoe) does not affect ex vivo platelet thromboxane production in humans. Eur J Clin Nutr 1996;50:772–4.
  32. Jie KSG, et al. Vitamin K status and bone mass in women with and without aortic atherosclerosis: A population based study. Calcif Tiff Int. 1996;59:352–6.
  33. Jung F, Mrowietz C, Kiesewetter H, Wenzel E. Effect of Ginkgo biloba on fluidity of blood and peripheral microcirculation in volunteers. Arzneimittelforschung 1990;40:589–93.
  34. Klipstein-Grobusch K, Launer LJ, Geleijnse JM, et al. Serum carotenoids and atherosclerosis. The Rotterdam Study. Atherosclerosis 2000;148:49–56.
  35. Korpela H, Kumpulainen J, Jussila E, et al. Effect of selenium supplementation after acute myocardial infarction. Res Comm Chem Pathol Pharmacol 1989; 65:249–52.
  36. Koscielny J, Klussendorf D, et al. The antiatherosclerotic effect of Allium sativum. Atherosclerosis. 1999 May;144(1):237–49.
  37. Kudolo GB, Wang W, et al. Oral ingestion of Ginkgo biloba extract reduces thiobarbituric acid reacting (TBAR) substances in washed platelets of healthy subjects. J Herb Pharmacother. 2003;3(4):1–15.
  38. Kuhlman DR, Schaefer CA, et al. Quercetin-induced induction of the NO/cGMP pathway depends on Ca2+-activated K+ channel-induced hyperpolarization-mediated Ca2+-entry into cultured human endothelial cells. Planta Med. 2005 Jun;71(6):520–4.
  39. Kuller LH, Evans RW. Homocysteine, vitamins, and cardiovascular disease. Circulation 1998;98:196–9 [editorial/review].
  40. Leaf A, Jorgensen MB, Jacobs AK, et al. Do fish oils prevent restenosis after coronary angioplasty? Circulation 1994;90:2248–57.
  41. Lee W, Min WK, et al. Long-term effects of green tea ingestion on atherosclerotic biological markers in smokers. Clin Biochem. 2005b Jan;38(1):84–7.
  42. Lee WJ, Lee IK, et al. Alpha-lipoic acid prevents endothelial dysfunction in obese rats via activation of AMP-activated protein kinase. Arterioscler Thromb Vasc Biol. 2005a Dec;25(12):2488–94.
  43. Lumb AB. Effect of dried ginger on human platelet function. Thromb Haemost 1994;7:110–1.
  44. Ma J, Hennekens CH, et al. A prospective study of fibrinogen and risk of myocardial infarction in the Physicians’ Health Study. J Am Coll Cardiol. 1999;33(5):1347–52.
  45. Machha A, Mustafa MR. Chronic treatment with flavonoids prevents endothelial dysfunction in spontaneously hypertensive rat aorta. J Cardiovasc Pharmacol. 2005 Jul;46(1):36–40.
  46. Manson JB, Miller JW. The effects of vitamin B12, B6, and folate on blood homocysteine levels. Ann NY Acad Sci 1992;669:197–204 [review].
  47. Massberg S, Enders G, et al. Fibrinogen deposition at the postischemic vessel wall promotes platelet adhesion during ischemia-reperfusion in vivo. Blood. 1999;94(11):3829–38.
  48. McSweeney JC, Cody M, et al. Women’s early warning symptoms of acute myocardial infarction. Circulation. 2003;108(21):2619–23.
  49. Morrison LM, Branwood AW, Ershoff BH, et al. The prevention of coronary arteriosclerotic heart disease with chondroitin sulfate A: Preliminary report. Exp Med Surg 1969;27:278–89.
  50. Morrison LM, Enrick NL. Coronary heart disease: Reduction of death rate by chondroitin sulfate A. Angiology 1973;24:269–82.
  51. Mosca L, Marcellini S, et al. Modulation of apoptosis and improved redox metabolism with the use of a new antioxidant formula. Biochem Pharmacol. 2002;63(7):1305–14.
  52. Mouren X, Caillard P, et al. Study of the antiischemic action of EGb 761 in the treatment of peripheral arterial occlusive disease by TcP02 determination. Angiology. 1994;45(6):413–7.
  53. Munteanu A, Zingg JM, et al. Anti-atherosclerotic effects of vitamin E—myth or reality? J Cell Mol Med. 2004;8(1):59–76.
  54. Oka RK, Szuba A, et al. A pilot study of L-arginine supplementation on functional capacity in peripheral arterial disease. Vasc Med. 2005 Nov;10(4):265–74.
  55. Olszewski AJ, McCully KS. Fish oil decreases serum homocysteine in hyperlipemic men. Coron Artery Dis 1993;4:53–60.
  56. Pace-Asciak CR, Rounova O, Hahn SE, et al. Wines and grape juices as modulators of platelet aggregation in healthy human subjects. Clin Chim Acta 1996;246(1–2):163–82.
  57. Packard CJ, O’Reilly DS, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med. 2000;343(16):1148–55.
  58. Packer L, Kraemer K, et al. Molecular aspects of lipoic acid in the prevention of diabetes complications. Nutrition. 2001;17(10):888–95.
  59. Phillipson BE, Rothrock DW, Connor WE, et al. Reduction of plasma lipids, lipoproteins, and apoproteins by dietary fish oils in patients with hypertriglyceridemia. N Engl J Med 1985;312:1210–6.
  60. Reiterer G, Toborek M, et al. Quercetin protects against linoleic acid-induced porcine endothelial cell dysfunction. J Nutr. 2004 Apr;134(4):771–5.
  61. Riba R, Nicolaou A, et al. Altered platelet reactivity in peripheral vascular disease complicated with elevated plasma homocysteine levels. Atherosclerosis. 2004;175(1):69–75.
  62. Rifai N, Ridker PM. High-sensitivity C-reactive protein: A novel and promising marker of coronary heart disease. Clin Chem. 2001;47(3):403–11.
  63. Rifai N. C-reactive protein and coronary heart disease: Diagnostic and therapeutic implications for primary prevention. Cardiovasc Toxicol. 2001;1(2):153–7.
  64. Rimm E. Micronutrients, Coronary Heart disease and cancer: Should we all be on supplements? Presented at the 60th Annual Biology Colloquium, Oregon State University, February 25, 1999.
  65. Rosenfeldt F, Marasco S, et al. Coenzyme Q10 therapy before cardiac surgery improves mitochondrial function and in vitro contractility of myocardial tissue. J Thorac Cardiovasc Surg. 2005 Jan;129(1):25–32.
  66. Rossouw JE, Anderson GL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–33.
  67. Sacks FM, Stone PH, Gibson CM, et al. Controlled trial of fish oil for regression of human coronary atherosclerosis. HARP Research Group. J Am Coll Cardiol 1995;25:1492–8.
  68. Salonen JT, Nyyssönen K, Salonen R, et al. Antioxidant supplementation in atherosclerosis prevention (ASAP) study: a randomized trial of the effect of vitamin E and C on 3-year progression of carotid atherosclerosis. J Intern Med 2000;248:177–86.
  69. Sano J, Inami S, et al. Effects of green tea intake on the development of coronary artery disease. Circ J. 2004 Jul;68(7):665–70.
  70. Sans S, Kesteloot H, et al. The burden of cardiovascular diseases mortality in Europe. Task Force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe. Eur Heart J. 1997;18(12):1231–48.
  71. Sasazuki S, Kodama H, et al. Relation between green tea consumption and the severity of coronary atherosclerosis among Japanese men and women. Ann Epidemiol. 2000 Aug;10(6):401–8.
  72. Selhub J, Jacques PF, Wilson PW, et al. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993;270:2693–8.
  73. Serafini M, Ghiselli A, Ferro-Luzzi A. In vivo antioxidant effect of green tea in man. Eur J Clin Nutr 1996;50:28–32.
  74. Shamberger RJ, Willis CE. Epidemiological studies on selenium and heart disease. Fed Proc 1976;35:578 [abstract #2061].
  75. Simoncini T, Mannella P, et al. Dehydroepiandrosterone modulates endothelial nitric oxide synthesis via direct genomic and nongenomic mechanisms. Endocrinology. 2003;144(8):3449–55.
  76. Sola S, Mir MQ, et al. Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: Results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study. Circulation. 2005 Jan 25;111(3):343–8.
  77. Sondergaard HP, Hansson LO, et al. The inflammatory markers C-reactive protein and serum amyloid A in refugees with and without posttraumatic stress disorder. Clin Chim Acta. 2004;342(1-2):93–8.
  78. Spagnoli LG, Orlandi A, et al. Propionyl-L-carnitine prevents the progression of atherosclerotic lesions in aged hyperlipemic rabbits. Atherosclerosis. 1995 Apr 7;114(1):29–44.
  79. Stephens NG, Parsons A, Schofield PM, et al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996;347:781–6.
  80. Suarna C, Hood RL, Dean RT, Stocker R. Comparative antioxidant activity of tocotrienols and other natural lipid-soluble antioxidants in a homogeneous system, and in rat and human lipoproteins. Biochim Biophys Acta 1993;1166:163–70.
  81. Tomeo AC, Geller M, Watkins TR, et al. Antioxidant effects of tocotrienols in patients with hyperlipidemia and carotid stenosis. Lipids 1995;30:1179–83.
  82. Touyz RM. Intracellular mechanisms involved in vascular remodelling of resistance arteries in hypertension: Role of angiotensin II. Exp Physiol. 2005 Jul;90(4):449–55. Review.
  83. Ubbink JB, Hayward WJ, van der Merwe A, et al. Vitamin requirements for the treatment of hyperhomocysteinemia in humans. J Nutr 1994;124:1927–33.
  84. Ubbink JB, van der Merwe A, Vermaak WJH, Delport R. Hyperhomocysteinemia and the response to vitamin supplementation. Clin Investig 1993;71:993–8.
  85. von Schacky C, Angerer P, Kothny W, et al. The effect of dietary omega-3 fatty acids on coronary atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999;130:554–62.
  86. Wiseman LR, Brogden RN. Propionyl-L-carnitine. Drugs Aging. 1998 Mar;12(3):243–8; discussion 249–50.
  87. Wu D, Liu L, et al. Vitamin E (E) increases prostacyclin (Pgi2) and prostaglandin (Pg) E2 production by human aorta endothelial cell (Haec) by differentially modulating cyclooxygenase (Cox) and phospholipase A2 (Pla2) activities. Experimental Biology. 2004;18(5 Pt Ii):a860.
  88. Yan LJ, Droy-Lefaix MT, Packer L. Ginkgo biloba extract (EGb 761) protects human low density lipoproteins against oxidative modification mediated by copper. Biochem Biophys Res Comm 1995;212:360–6.
  89. Yin WH, Chen JW, et al. L-arginine improves endothelial function and reduces LDL oxidation in patients with stable coronary artery disease. Clin Nutr. 2005 Dec;24(6):988–97.